← Back to Screener
REGENXBIO Inc. (RGNX)
Price$9.19
Favorite Metrics
Price vs S&P 500 (26W)-27.39%
Price vs S&P 500 (4W)7.22%
Market Capitalization$483.87M
All Metrics
Book Value / Share (Quarterly)$2.02
P/TBV (Annual)1.66x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)14.78%
Cash Flow / Share (Quarterly)$-2.48
Price vs S&P 500 (YTD)-37.64%
Gross Margin (TTM)88.09%
Net Profit Margin (TTM)-113.75%
EPS (TTM)$-3.75
10-Day Avg Trading Volume0.56M
EPS Excl Extra (TTM)$-3.75
Revenue Growth (5Y)1.97%
EPS (Annual)$-3.76
ROI (Annual)-66.91%
Gross Margin (Annual)88.09%
Net Profit Margin (5Y Avg)-179.96%
Cash / Share (Quarterly)$4.52
Revenue Growth QoQ (YoY)43.00%
ROA (Last FY)-42.80%
Revenue Growth TTM (YoY)104.54%
EBITD / Share (TTM)$-2.82
ROE (5Y Avg)-79.66%
Operating Margin (TTM)-94.58%
Cash Flow / Share (Annual)$-2.48
P/B Ratio4.71x
P/B Ratio (Quarterly)7.10x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)3.73x
Net Interest Coverage (TTM)-4.91x
ROA (TTM)-37.83%
EV / EBITDA (TTM)5.32x
EPS Incl Extra (Annual)$-3.76
Current Ratio (Annual)2.38x
Quick Ratio (Quarterly)2.28x
3-Month Avg Trading Volume0.88M
52-Week Price Return47.87%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$8.25
P/S Ratio (Annual)2.84x
Asset Turnover (Annual)0.38x
52-Week High$16.19
Operating Margin (5Y Avg)-174.20%
EPS Excl Extra (Annual)$-3.76
CapEx CAGR (5Y)-38.26%
Tangible BV CAGR (5Y)23.04%
26-Week Price Return-23.40%
Quick Ratio (Annual)2.28x
13-Week Price Return-37.93%
Total Debt / Equity (Annual)1.82x
Current Ratio (Quarterly)2.38x
Enterprise Value$636.423
Revenue / Share Growth (5Y)-4.43%
Asset Turnover (TTM)0.33x
Book Value / Share Growth (5Y)-27.50%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-113.75%
Cash / Share (Annual)$4.52
3-Month Return Std Dev88.60%
Gross Margin (5Y Avg)69.44%
Net Income / Employee (TTM)$-1
ROE (Last FY)-188.72%
Net Interest Coverage (Annual)-4.93x
EPS Basic Excl Extra (Annual)$-3.76
P/FCF (TTM)14.84x
Receivables Turnover (TTM)7.28x
Total Debt / Equity (Quarterly)1.82x
EPS Incl Extra (TTM)$-3.75
Receivables Turnover (Annual)7.28x
ROI (TTM)-56.26%
P/S Ratio (TTM)2.84x
Pretax Margin (5Y Avg)-179.44%
Revenue / Share (Annual)$3.30
Tangible BV / Share (Annual)$11.92
Price vs S&P 500 (52W)18.04%
Year-to-Date Return-35.00%
5-Day Price Return4.46%
EPS Normalized (Annual)$-3.76
ROA (5Y Avg)-31.92%
Net Profit Margin (Annual)-113.75%
Month-to-Date Return11.69%
Cash Flow / Share (TTM)$-5.59
EBITD / Share (Annual)$-2.82
Operating Margin (Annual)-94.58%
LT Debt / Equity (Annual)1.43x
ROI (5Y Avg)-48.11%
LT Debt / Equity (Quarterly)1.43x
EPS Basic Excl Extra (TTM)$-3.75
P/TBV (Quarterly)2.36x
P/B Ratio (Annual)7.10x
Pretax Margin (TTM)-113.75%
Book Value / Share (Annual)$2.02
Price vs S&P 500 (13W)-38.62%
Beta1.16x
P/FCF (Annual)3.59x
Revenue / Share (TTM)$3.29
ROE (TTM)-103.12%
52-Week Low$5.81
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.21
4.21
4.21
4.21
Industry Peers — Biological Products(88)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
RGNXREGENXBIO Inc. | 2.84x | 104.54% | 88.09% | — | $9.19 |
AMGNAmgen Inc | 5.13x | 9.95% | 73.30% | 2.93% | $349.39 |
GILDGilead Sciences Inc | 5.84x | 2.40% | 78.83% | 133.64% | $138.55 |
ARGXargenx SE American Depositary Shares | 12.46x | 89.56% | 150.91% | — | $828.35 |
BNTXBioNTech SE American Depositary Share | 8.75x | -11.81% | 84.21% | — | $102.12 |
BIIBBiogen Inc. Common Stock | 2.60x | 2.22% | 75.69% | -18.77% | $176.02 |
MRNAModerna, Inc. Common Stock | 11.02x | -39.93% | 70.32% | — | $54.68 |
NBIXNeurocrine Biosciences Inc | 4.49x | 21.45% | 98.18% | 2.31% | $128.41 |
EXELExelixis Inc | 4.96x | 6.85% | 96.39% | 31.10% | $44.38 |
TECHBio-Techne Corp. | 7.60x | 1.64% | 66.60% | -20.58% | $57.36 |
HALOHalozyme Therapeutics, Inc. | 5.74x | 37.55% | 83.62% | 22.89% | $66.64 |
About
Regenxbio is a clinical-stage biotechnology company developing gene therapies using its proprietary NAV Technology Platform based on adeno-associated virus (AAV) vectors. The company targets retinal, neuromuscular, and neurodegenerative diseases by delivering genes to cells to correct genetic defects or enable therapeutic protein production. Its pipeline addresses unmet medical needs in genetic and degenerative disorders.